Temporarily not available outside of China.The online Datasheet here is only a general version, for batch specific information please refer to the hard copy included in the product shipping package.

uPAR/PLAUR ELISA Kit, Human: 产品信息

Solid Phase Sandwich ELISA (quantitative)
2.32 pg/mL
4.69-300 pg/mL
Recognizes both recombinant and natural Human uPAR/PLAUR
  Intra-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 41.61 74.99 164.28
SD 2.49 1.70 7.97
CV(%) 6.0% 2.3% 4.9%
  Inter-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 37.33 75.28 167.37
SD 2.65 2.84 7.47
CV(%) 7.1% 3.8% 4.5%
The recovery of Human PLAUR spiked to different levels throughout the range of the assay in related matrices was evaluated.
serum (n=3)
Average % Recovery
81 -97%
  Recovery of detected
1:2 98%
1:4 110%
1:8 120%
1:16 123%
ELISA 试剂盒(即用型)组分
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
This uPAR/PLAUR ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human uPAR/PLAUR protein in Serum . It contains recombinant Human uPAR/PLAUR, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
This ELISA Kit is shipped at ambient temperature.
Unopened Kit: Store at 2 - 8℃
Opened/Reconstituted Reagents: Please refer to CoA

uPAR/PLAUR ELISA Kit, Human: 图片

This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
This assay recognizes both recombinant and natural Human UPAR. The factors listed below were prepared at 50 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed. Preparations of the following factors at 5 ng/mL in a mid-range recombinant human UPAR control were assayed for interference. No significant interference was observed.

uPAR/PLAUR ELISA Kit, Human: 别称

CD87 ELISA Kit, Human; U-PAR ELISA Kit, Human; UPAR ELISA Kit, Human; URKR ELISA Kit, Human


Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.
plasminogen activator, urokinase receptor
  • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
  • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
  • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
  • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
添加购物车成功! 添加购物车失败!请再次尝试 正在更新购物车,请稍后 U.S.A.